Thermo Fisher's Q3 earnings boosted by COVID-19 sales
October 21, 2020 -- Products related to the novel coronavirus are spelling success for Thermo Fisher, which reported that revenue was up by 36% in the third quarter to $8.52 billion, compared with $6.27 billion the same period last year.
Poseida, TScan partner on allogenic TCR therapies for COVID-19
October 21, 2020 -- Poseida Therapeutics and TScan Therapeutics are joining forces to develop T-cell receptor (TCR) therapies for the treatment of COVID-19.
Immunic gets funding for lead COVID-19 therapeutic candidate
October 20, 2020 -- Immunic has inked a 24.5 million euro ($29 million U.S.) financing agreement with the European Investment Bank.
Proteintech acquires ChromoTek
October 20, 2020 -- Proteintech, a German-based producer of antibodies, proteins, and immunoassays, has acquired ChromoTek, a manufacturer of camelid single-domain antibodies (aka nanobodies).
HJF to develop herpes virus vaccines
October 20, 2020 -- The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) and Citranvi Biosciences have signed an exclusive licensing agreement to develop vaccine technologies to prevent cytomegalovirus and Epstein-Barr virus infections.
Aridis touts positive preclinical results for COVID-19 mAb treatment
October 19, 2020 -- Anti-infective therapies firm Aridis Pharmaceuticals has developed an inhalable highly neutralizing monoclonal antibody (mAb) that eradicated the novel coronavirus in infected rodents.
Akron, Synairgen partner on IFN-beta treatment for COVID-19
October 19, 2020 -- Cell therapeutics company Akron Biotechnology and respirator drug development firm Synairgen have partnered to advance interferon-beta (IFN-beta) treatment for patients with COVID-19.
Ultimovacs touts positive early clinical results for universal cancer vaccine
October 19, 2020 -- Ultimovacs reported five-year overall survival data from its phase I clinical trial evaluating UV1, a universal cancer vaccine candidate, in patients with non-small cell lung cancer.
Bristol Myers Squibb advances cancer immunotherapy in Europe
October 16, 2020 -- The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Bristol Myers Squibb's nivolumab (Opdivo).
CHMP recommends approval for Janssen's mAb in psoriatic arthritis
October 16, 2020 -- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval for the expanded use of guselkumab (Tremfya), a monoclonal antibody (mAb) from the Janssen Pharmaceutical Companies of Johnson & Johnson.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter